DXS InternationalAQSE:DXSP EBITDA Margin % is -3.63% as of Apr. 2025. The stock has 2 warning signs investors should review. Among 668 Healthcare Providers & Services companies, DXS International ranks worse than 76.95% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. DXS International's EBITDA for the
six
months ended in Apr. 2025 was £-0.13 Mil. DXS International's Revenue for the
six
months ended in Apr. 2025 was £3.47 Mil. Therefore, DXS International's EBITDA margin for the quarter that ended in Apr. 2025 was -3.63%.
DXS International (AQSE:DXSP) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
DXS International EBITDA Margin % Related Terms
DXS International EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for DXS International's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AQSE:DXSP vs VEEV, BTSG, TEM: EBITDA Margin % Comparison
For the Health Information Services subindustry, DXS International's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DXS International EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, DXS International's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where DXS International's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DXS International (AQSE:DXSP) has a EBITDA Margin % of -3.63% as of Apr. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on DXS International and its competitors. According to the industry distribution chart, DXS International ranks #514 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 76.9%.
Is DXS International's EBITDA Margin % too high?
DXS International's current EBITDA Margin % is -3.63%. Based on the distribution chart, DXS International ranks #514 out of 668 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers.
How does DXS International's EBITDA Margin % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, DXS International ranks #514 out of 668 companies for EBITDA Margin %. This places DXS International in the lower half of its industry. The industry median EBITDA Margin % is 10.21. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on DXS International and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DXS International's current EBITDA Margin % is -3.63%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DXS International stock overvalued right now?
Based on GuruFocus' analysis, DXS International (AQSE:DXSP) is currently considered Possible Value Trap. The stock's GF Value™ is £0.02, compared to a current price of £0.01 — trading 37.5% below its estimated fair value. The current EBITDA Margin % is -3.63%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For DXS International (AQSE:DXSP), the current EBITDA Margin % is -3.63% as of Apr. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
DXS International PLC is engaged in the development and distribution of clinical decision support systems for General Practitioners, nurses, and retail pharmacies in the United Kingdom and South Africa. Its commercial activities include licensing DXS products to various ICBs, offering e-detailing opportunities to the pharmaceutical industry and the UK primary care sector, and licensing its technology to healthcare publishers. The company's products include BestPathway and Point-of-Care ExpertCare.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AQSE:DXSP has been successfully added to your 